Medix Biochemica Launches Refreshed and Expanding Brand to Reflect Growing IVD Products Portfolio

The company hopes that its accelerated growth will establish its status as the ultimate IVD raw materials supplier. A new website brings to life a brand-new creative campaign that communicates every aspect of Medix’s expertise – alongside an aspirational corporate identity to reflect the company’s ambitions.

In line with its commitment to offering its customers the most comprehensive IVD raw materials portfolio in the business, Medix has acquired several companies, each with their own expertise across the IVD market. In 2019, Lee Biosolutions was acquired, followed by EastCoast Bio and Biostride in 2020, Diaclone just last year and, most recently, myPOLS Biotec GmbH, which will strengthen its existing molecular diagnostics division, MedixMDx. This integration has helped Medix broaden its portfolio to over 5,000 products in categories such as molecular reagents, enzymes, biospecimens and immunoreagents.

Based on customer feedback and its aim to create a better business for its customers, has launched brand new website that will be the go-to place for its customers. Whether it’s a streamlined product experience or a specific service such as antibody, DNA or RNA polymerase engineering, customers will be able to find out more and contact the company directly to discuss their needs. The launch is another step towards Medix’s vision to be the first-choice, independent raw material partner for the IVD industry.

“The launch of the new Medix Biochemica brand is the culmination of years of hard work,” said Steve Ferguson, CEO of Medix Biochemica. “We are so excited to be able to offer our customers more services, more expertise, more product choices than ever before. And most importantly, still with the same quality and care our customers are used to receiving from Medix Biochemica.”

Related Links:
Medix Biochemica